New Legislation & Guidance for Pharmacovigilance Reporting has been applied in the European Union (EU) since July 2012. To assist in its implementation with sponsors, applicants and license holders, a series of Guidance Documents were written, which would replace the current set of Volume 9A of the Rules Governing Medicinal Products in the EU. The legal framework for pharmacovigilance on Medicinal Products for Human Use has now been updated, through an amended EU Regulation (No 1235/2010) and Directive (2010/84/EC).
This webinar by expert speaker Robert Russell is focused on understanding the EU Pharmacovigilance Reporting System requirements now in effect across the European Union. The New Guidance document Modules on Good Pharmacovigilance Practices (GVP) have been updated. License holders with commercial medicinal products on the market are expected to have an EU-compliant PV System and PV Manual ready for inspection by any Healthcare Authority or the EMA.
These inspections have already been in progress and can happen unannounced. Join this session to know the regulatory and guidance updates as well as thoughts on how member states having competent authorities have worked towards implementation. These regulatory changes are also going to impact the EU Clinical Trial Regulations as well as the sponsor’s expectations when it comes to protecting public and patient health – before, after and during clinical studies.
This session will provide you a thorough knowledge of all the updated frameworks surrounding Good Pharmacovigilance Practices (GVP), the EU regulation updates, PV guidance models and Directives that have already been published and launched. The webinar is specifically designed to simplify understanding of new requirements and equip you with latest information on what is being believed by the European Commission when it comes to improvement across the region.
Who Should Attend
This Webinar will provide invaluable assistance to all personnel in the Pharmaceutical, Biotechnology and CRO industry involved in maintaining Compliance across the responsibilities in European Pharmacovigilance such as:
Ask a question at the Q&A session following the live event and get advice unique to your situation, directly from our expert speaker.
- Dr. David Lim
Robert Russell, holds a B.S. and M.S.in Chemistry. Prior to founding RJR Consulting, Inc., a Global Regulatory Consulting firm in 2001, Mr. Russell spent 28 years in the Pharmaceutical and Medical Device Industry with two Fortune 150 firms working in CMC, Global Business Development and Regulatory Affairs.